A Look At Bruker (BRKR) Valuation After Mixed Earnings And Soft 2026 Growth Outlook

Simply Wall St

Sat, February 14, 2026 at 1:26 PM GMT+9 2 min read

In this article:

BRKR

-2.67%

BRKRP

+0.80%

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

Bruker (BRKR) shares sold off after mixed fourth quarter 2025 results, as revenue slightly topped expectations while adjusted earnings per share missed forecasts and 2026 guidance pointed to relatively modest organic growth.

See our latest analysis for Bruker.

The latest results and 2026 guidance have reset expectations, and that shift is showing up in the chart, with a 1 day share price return of 2.67% decline, a 30 day share price return of 25.70% decline, and a 1 year total shareholder return of 26.68% decline. This indicates fading momentum as investors reassess Bruker’s growth outlook and risk profile despite recent product launches and acquisitions.

If Bruker’s earnings reset has you rethinking where growth could come from next, it may be worth scanning our 25 healthcare AI stocks as a starting list of potential ideas.

With the shares down sharply and trading at a reported intrinsic discount of about 28%, plus roughly 36% below the average analyst price target, is Bruker a reset story on sale, or is the market already discounting future growth?

Most Popular Narrative: 32.9% Undervalued

Bruker’s most followed narrative pegs fair value at $54.43 per share versus the last close of $36.51, and the gap hinges on a detailed earnings and margin reset story.

The company’s pipeline of recent innovations (e.g., next-generation tims mass spectrometry, spatial biology, automated diagnostics) positions it to benefit from sustained investment in personalized medicine, genomics, and high-throughput scientific R&D, supporting both future revenue expansion and favorable product mix improvements.

Read the complete narrative.

For readers interested in what revenue trajectory and margin rebuild would need to occur to support that fair value, and how the future P/E is incorporated, the full narrative lays out the specific growth, profitability, and discount rate assumptions driving that $54.43 number.

Result: Fair Value of $54.43 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, you still need to weigh the risk that research funding stays soft and order momentum weakens further, which could pressure both revenue and margin expectations.

Find out about the key risks to this Bruker narrative.

Build Your Own Bruker Narrative

If you look at the numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a custom view in just a few minutes and then Do it your way.

Story Continues  

A great starting point for your Bruker research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Bruker is only one part of your watchlist, now is the time to widen your search and pressure test your next moves with data driven stock ideas.

Spot potential mispricings early by scanning our 53 high quality undervalued stocks that combine quality fundamentals with attractive valuations.

Strengthen your income stream by reviewing the 13 dividend fortresses that could help you focus on higher yielding opportunities.

Prioritise resilience by checking the 85 resilient stocks with low risk scores so you do not miss companies with more balanced risk profiles.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include BRKR.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info